ABUS

Arbutus Biopharma
ABUS

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$599.48M
EV
$492.37M
Shares Outstanding
191.53M
Beta
1.21

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$5.36
P/E 2025E
-
P/Revenue 2025E
104.48x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Arbutus Biopharma Corporation

gainify
ABUS

Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic...

Sector

Healthcare

Industry

Biotechnology

CEO

McElhaugh, Michael

Employees

44

IPO Date

2007-07-26

Headquarters

701 Veterans Circle, Warminster, Pennsylvania, 18974, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

COMPANY

Pricing

Dashboard

About Us

Contact Us

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.